On 6 June 2012, orphan designation (EU/3/12/999) was granted by the European Commission to AiCuris GmbH & Co. KG, Germany, for letermovir for the treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity.
The sponsorship was transferred to Merck Sharp & Dohme Limited, United Kingdom, in March 2013.
The sponsorship was transferred to Merck Europe B.V., The Netherlands, in June 2018.
|Disease / condition||
Treatment of cytomegalovirus disease in patients with impaired cell-mediated immunity
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.